Tiludronate disodium hemihydrate is a bisphosphonate compound primarily used in the treatment of Paget's disease and other bone disorders. It functions by inhibiting osteoclast-mediated bone resorption, thereby helping to maintain bone density and strength. The substance appears as a white to off-white crystalline powder and is soluble in water, which facilitates its administration. Its molecular structure includes two phosphonate groups, contributing to its ability to bind to hydroxyapatite in bone tissue. The hemihydrate form indicates the presence of water molecules in its crystalline structure, which can influence its stability and solubility. Tiludronate disodium hemihydrate is typically administered orally and is known for its relatively favorable safety profile, although potential side effects may include gastrointestinal disturbances and, in rare cases, osteonecrosis of the jaw. As with any medication, it is essential to use it under medical supervision, considering individual patient factors and potential interactions with other drugs.

Tiludronate disodium hemihydrate

155453-10-4: Disodium (4-chlorophenylthio)methylenediphosphonate hemihydrate

Tiludronate: an oral bisphosphonate for bone disorder research; inhibits osteoclasts and reduces inflammation.

CAS 155453-10-4: Tiludronate disodium hemihydrate

Tiludronate disodium hemihydrate

Ref: TM-T39037